NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Descending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00078-1098-20 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-94 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
00003-3756-14 | 00003-3756 | nivolumab | OPDIVO | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Aug. 30, 2021 | In Use | |
24658-0702-01 | 24658-0702 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0702-05 | 24658-0702 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0703-01 | 24658-0703 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0703-05 | 24658-0703 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use |
Found 10,000 results in 6 milliseconds — Export these results